Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.

PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW<300Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

[1]  Aaron J. Oakley,et al.  Fragment-Based Screening by Protein Crystallography: Successes and Pitfalls , 2012, International journal of molecular sciences.

[2]  Jian Ding,et al.  Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond , 2015, Medicinal research reviews.

[3]  K. Kinzler,et al.  Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer , 2016, Nature Communications.

[4]  David T Manallack,et al.  The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. , 2005, Journal of medicinal chemistry.

[5]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[6]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[7]  L. Mario Amzel,et al.  Structural basis of nSH2 regulation and lipid binding in PI3Kα , 2014, Oncotarget.

[8]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[9]  Rocco Caliandro,et al.  Protein crystallography and fragment-based drug design. , 2013, Future medicinal chemistry.

[10]  J. Castillo,et al.  CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies , 2012, Expert opinion on investigational drugs.

[11]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[12]  Fei Long,et al.  REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. , 2004, Acta crystallographica. Section D, Biological crystallography.

[13]  Ji Zhang,et al.  Chemical Constituents and Insecticidal Activity of the Essential OilsExtracted from Artemisia giraldii and Artemisia rubripes against TwoStored Product Insects , 2016 .

[14]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[15]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[16]  M. Kulesz-Martin,et al.  Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling , 2015, Oncogene.

[17]  C. Lindsley.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. , 2010, Current topics in medicinal chemistry.

[18]  A. Johnson,et al.  Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[20]  Doriano Fabbro,et al.  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. , 2013, Bioorganic & medicinal chemistry letters.

[21]  Lei Nie,et al.  FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma , 2015, Clinical Cancer Research.

[22]  Simon Ng,et al.  Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. , 2011, ACS medicinal chemistry letters.

[23]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[24]  Q. Peng,et al.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review) , 2015, International journal of oncology.

[25]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[26]  Marcel L Verdonk,et al.  Detection of secondary binding sites in proteins using fragment screening , 2015, Proceedings of the National Academy of Sciences.

[27]  K. Huber,et al.  Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening , 2015, Proceedings of the National Academy of Sciences.

[28]  J. Backer,et al.  Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit , 1998, Molecular and Cellular Biology.

[29]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[30]  Roger L. Williams,et al.  Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases , 2011, Oncogene.

[31]  Tom Halgren,et al.  New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.

[32]  R. Copeland,et al.  Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .

[33]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[34]  G. Prestwich,et al.  Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. , 2003, Combinatorial chemistry & high throughput screening.

[35]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[36]  A. Özer,et al.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer , 2016, Tumor Biology.

[37]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[38]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[39]  M. Clausen,et al.  Allosteric small-molecule kinase inhibitors. , 2015, Pharmacology & therapeutics.

[40]  Yuan Zhang,et al.  Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer , 2016, Oncotarget.

[41]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[42]  Paul W Smith,et al.  A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening* , 2016, The Journal of Biological Chemistry.

[43]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.